ADA

Diabetes investigator John Buse, MD, PhD, says laser focus on reducing T2D risk factors is equally as important as using the next right drug against the disease.

Dr Buse’s in-depth review of the GRADE study is followed by a discussion of the keen need for more comparative research and the many new questions the results have raised about optimal T2D therapy.

ADA 2021. A subgroup analysis of the FIDELIO-DKD trial showed that finerenone use was beneficial regardless of baseline insulin use among patients with T2D and CKD.

Preliminary GRADE study results showed that liraglutide and insulin glargine added to metformin maintained A1c level in target range longer than glimepiride or sitagliptin.

ADA 2021. Dapagliflozin was found to reduce type 2 diabetes incidence among patients with chronic kidney disease in a prespecified analysis of the DAPA-CKD trial.

ADA 2021. A prespecified subanalysis of FIDELIO-DKD found primary and secondary renal and CV endpoints consistent whether or not SGLT2 inhibitors were on board at study baseline.

Data released today at the American Diabetes Association 81st Scientific Sessions on a spike in new onset pediatric T2D at a single center during COVID-19 may signal much wider incidence.

Leading international diabetes researchers and clinicians will use the ADA's 81st annual Scientific Sessions as an ideal classroom to examine pandemic impact on diverse populations with diabetes.

The upcoming ADA virtual 81st Scientific Sessions will feature 5 sessions on the latest diabetes developments learned during the initial phases of the COVID-19 pandemic.

The American Diabetes Association 2021 Scientific Sessions run from June 25 to 29. This short slide show highlights 6 clinical trial updates that are a "must see" for primary care clinicians.

VIDEO: Kieran Docherty, MBChB, discusses results of the DAPA-HF analysis on the impact of background T2D therapy on clinical outcomes in patients with T2D and HFrEF.

ADA 2020. Average A1c for a recent young cohort with type 2 diabetes was 8.5%, according to research presented at the ADA Virtual Scientific Sessions.

Physicians’ CKD awareness in T2D is linked with CKD severity, suggests a new study presented this week at the American Diabetes Association’s 80th Virtual Scientific Sessions.

VIDEO: Silvio Inzucchi, MD, discusses results of a prespecified analysis of the DAPA-HF trial, which found that dapagliflozin reduced new onset diabetes by 32% in patients with heart failure.

ADA 2020: Glycemic control was worse for black patients who experienced hurried interaction with healthcare providers than for those who did not, a new study reports.

ADA 2020. Improvement in glycemic control among US veterans was seen across 5 study sites and was sustained at 18 months after study initiation, says study reported at the ADA 80th Virtual Scientific Sessions.

ADA 2020. An investigational once-weekly insulin proved comparable in safety and efficacy to traditional once-daily insulin glargine in findings presented at the ADA 80th Annual Virtual Scientific Sessions.

ADA 2020. Dapagliflozin reduced new onset type 2 diabetes in patients with heart failure with reduced ejection fraction, according to a study released today at the ADA 80th Virtual Scientific Sessions.

ADA2020: Empagliflozin significantly, durably delays need for insulin and for large dose increases, in patients with type 2 diabetes and cardiovascular disease, finds study presented at ADA 80th Scientific Sessions.

ADA 2020: A new automatic insulin delivery system improves glycemic control in young people with type 1 diabetes, according to research presented at the American Diabetes Association Virtual Scientific Sessions.

The American Diabetes Association kicks off its Virtual 80th Scientific Sessions on Friday, June 12, 2020. Here is our guide to top sessions.

Who is at risk for T2DM? How often should you screen? What are the cut offs for Dx? Revisit the basics in 5 minutes or less.

Studies summarized in this slide show focus on fine-tuning insulin-containing regimens to enhance glucose control and avoid variability.

Glycemic variability fuels hypoglycemia but in one study from ADA 2017 is found to actually help predict hypoglycemic events.

Cardiovascular risk/benefit profiles of pioglitazone and the SGLT2 inhibitor class are summarized, based on reports at ADA 2017.

A1C vs FPG to diagnose prediabetes; prediabetes and CHF; and how much weight loss is too much? Reports from ADA 2017.

Insulin degludec vs glargine--which costs less per anum and why? We summarize this study and 2 other direct insulin comparisons reported at ADA 2017.

When to start screening for B12 deficiency in your diabetes patients taking metformin? We review a dose-response diet study plus 2 others on oral drugs.

A how-to overview of how to advance therapy for hyperglycemia and ASCVD risk factors in patients with T2DM.

Self-monitoring of blood glucose is critical for all patients with T2DM and their physicians.The numbers help modify behavior and Rx.